Thymosin beta-4 in rats after stroke
A rat embolic-stroke dose-response study of full-length thymosin beta-4 examined 2-18 mg/kg by intraperitoneal administration. The modeled optimum was near 3.75 mg/kg; 18 mg/kg gave no benefit. This was a rat stroke model using the parent protein, with neither TB-500 fragment nor BPC-157 in combination.
The failed high dose is where my BPC-157 TB-500 dosage questions begin. A tidy progression from a little to a lot can conceal a response that rises and falls. The experiment gives a specific reason to doubt generic loading arguments, while establishing no human dose or schedule.
BPC-157 animal doses
The rat Achilles experiment reported BPC-157 at 10 μg/kg or 10 ng/kg, administered intraperitoneally. Rat gastric-ulcer cytoprotection work is summarized at 400-800 ng/kg in the gastric peptide literature. Each figure describes a single-compound animal experiment.
A commercially printed combined mass, such as 10 mg + 10 mg, is a packaging convention. No peer-reviewed combination dose-finding study validates that ratio. I see an unsupported leap whenever a fixed mass is treated as though it already answered questions about identity, absorption, interaction and safety.
Half-life
The pharmacokinetic summary in the references records BPC-157's elimination half-life as under 30 minutes in a rat/dog study. There is no validated human half-life for either constituent at research-use doses, and none for the blend.
The human IV studies of full-length thymosin beta-4 showed dose-proportional pharmacokinetics, with half-life increasing at higher doses. The recombinant full-length study also concerns the parent protein. These data cannot assign the Ac-LKKTETQ fragment a human half-life.
A short half-life describes how quickly a measured substance leaves plasma. It leaves the duration of a tissue response, the effects of combining compounds and any human regimen unresolved.
Wolverine injection, oral products and spray
“Wolverine injection” usually refers in community discussion to subcutaneous or intramuscular use. Much of the underlying rodent tendon and stroke work used intraperitoneal administration. Human IV studies used full-length thymosin beta-4, while individual-compound wound and tendon studies also include local and topical routes.
The BPC 157 TB 500 oral question starts with BPC-157's description as a stable gastric peptide and its peroral animal research. Oral combination products lack validated pharmacokinetics; controlled human data do not establish oral bioavailability for the blend. A Wolverine spray claim faces the same absence of controlled human combination evidence, as bounded by the human and review literature.
Route changes the question an experiment answers. I cannot rank spray, oral and injectable formats by effectiveness when a controlled comparison of the blend is missing.
Reconstitution and identity
Reconstitution means dissolving a freeze-dried preparation. Questions about it often assume that the named contents, amount and BPC-157:TB-500 ratio have already been verified. The 2026 review of unapproved musculoskeletal peptides describes the uncertainty and potential harm around non-regulated availability.
The chemical identity of the TB-500 fragment adds another complication: much of its borrowed efficacy record concerns the much larger parent protein. No validated human combination dose, cycle or loading-and-maintenance schedule resolves those issues. This page records study conditions; a preparation or administration procedure would require knowledge the blend's evidence does not supply.